Short Interest in ICU Medical, Inc. (NASDAQ:ICUI) Drops By 6.3%

ICU Medical, Inc. (NASDAQ:ICUI) was the recipient of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,180,000 shares, a drop of 6.3% from the July 31st total of 1,260,000 shares. Currently, 5.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 193,800 shares, the days-to-cover ratio is presently 6.1 days.

ICU Medical Trading Up 0.2 %

Shares of NASDAQ ICUI traded up $0.22 during midday trading on Friday, reaching $145.25. The stock had a trading volume of 55,704 shares, compared to its average volume of 189,150. The firm has a market cap of $3.51 billion, a price-to-earnings ratio of -71.80 and a beta of 0.63. ICU Medical has a twelve month low of $128.90 and a twelve month high of $212.43. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.97 and a current ratio of 2.57. The company’s 50 day moving average price is $163.19 and its 200 day moving average price is $172.16.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.43. ICU Medical had a negative net margin of 2.11% and a positive return on equity of 6.93%. The firm had revenue of $549.31 million for the quarter, compared to the consensus estimate of $562.90 million. As a group, sell-side analysts expect that ICU Medical will post 5.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ICUI shares. 51job reissued a “maintains” rating on shares of ICU Medical in a report on Tuesday, May 9th. KeyCorp boosted their price target on shares of ICU Medical from $200.00 to $216.00 in a research report on Tuesday, May 9th. Finally, StockNews.com started coverage on shares of ICU Medical in a research report on Thursday, August 17th. They issued a “hold” rating on the stock.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 194 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $190.41, for a total value of $36,939.54. Following the transaction, the director now directly owns 1,481 shares of the company’s stock, valued at approximately $281,997.21. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Elisha W. Finney sold 194 shares of ICU Medical stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $190.41, for a total transaction of $36,939.54. Following the sale, the director now directly owns 1,481 shares of the company’s stock, valued at approximately $281,997.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 30,000 shares of ICU Medical stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $180.02, for a total transaction of $5,400,600.00. Following the sale, the chief executive officer now directly owns 23,677 shares in the company, valued at $4,262,333.54. The disclosure for this sale can be found here. Insiders have sold a total of 60,194 shares of company stock valued at $11,097,640 in the last ninety days. 7.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Neuberger Berman Group LLC lifted its position in shares of ICU Medical by 16.6% during the 4th quarter. Neuberger Berman Group LLC now owns 443,248 shares of the medical instruments supplier’s stock valued at $69,803,000 after acquiring an additional 63,181 shares during the period. JPMorgan Chase & Co. lifted its position in shares of ICU Medical by 1.1% during the 4th quarter. JPMorgan Chase & Co. now owns 754,421 shares of the medical instruments supplier’s stock valued at $118,806,000 after acquiring an additional 8,256 shares during the period. Van ECK Associates Corp raised its holdings in ICU Medical by 380.0% during the fourth quarter. Van ECK Associates Corp now owns 2,683 shares of the medical instruments supplier’s stock worth $423,000 after buying an additional 2,124 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in ICU Medical by 7.8% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 578,533 shares of the medical instruments supplier’s stock worth $91,107,000 after buying an additional 41,756 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its holdings in ICU Medical by 0.3% during the first quarter. Eagle Asset Management Inc. now owns 65,279 shares of the medical instruments supplier’s stock worth $10,768,000 after buying an additional 186 shares during the last quarter. Institutional investors and hedge funds own 91.49% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.